2 Growth Stocks Cathie Wood Is Buying Non-Stop
Cathie Wood is most known for her bold, tech-first investing. She was an outlier during the 2021 boom as her aggressive bets paid off in spades. This turned ARK Invest from an…
Headquartered in Pleasanton, CA Fiscal year ends December NASDAQ: TXG 10xgenomics.com
10x Genomics is a life science technology company that develops integrated solutions — instruments, consumables, and software — for single cell and spatial biology research. Its products enable academic and translational researchers and biopharmaceutical companies to analyze biological systems at high resolution and scale, with applications spanning oncology, immunology, neuroscience, and other fields. The company's spatial portfolio includes Visium and Xenium platforms, while its single cell offerings include the Chromium platform and the recently launched Atera system. 10x Genomics also generates revenue from services and patent licensing. The company recently expanded into multiomics through the acquisition of Proteintech Genomics, adding protein detection capabilities, and is pursuing diagnostics applications through collaborations with major medical institutions. Updated
Cathie Wood is most known for her bold, tech-first investing. She was an outlier during the 2021 boom as her aggressive bets paid off in spades. This turned ARK Invest from an…
Don’t look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns. Notably, the flagship…
Thursday's additional top analyst upgrades and downgrades were on Analog Devices, Bed Bath & Beyond, Hasbro, Krispy Kreme, 10X Genomics, Verizon Communications and more.
Friday's additional top analyst upgrades and downgrades included Allogene Therapeutics, CSX, Norfolk Southern, Qualcomm, Toyota and Yelp.
Stocks were trading lower in Thursday's premarket. Here is a look at the leaders and the laggards.
10x Genomics is a life science technology company that develops integrated solutions — instruments, consumables, and software — for single cell and spatial biology research.
24/7 Wall St.'s 12-month price target for TXG is $68.65, rated Hold. The Wall Street consensus target is $62.13. TXG price prediction →